TrialPath
Recruiting

BRE-13: Mediterranean Diet

NCT07869355 · University of Illinois Chicago
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer
About this study
Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.
Eligibility criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Newly diagnosed stage I-III luminal breast cancer 3. Planned surgical resection at UI Health 4. Ability to speak, read, write, and understand English 5. A Mediterranean Eating Pattern for Americans (MEPA-III) score \<13 indicating that they do not currently follow a MedDiet; 6. ECOG performance status of 0 or 1. Exclusion Criteria: 1. Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet; 2. Lack of access to a space to safely store and reheat foods items; 3. Living in facility that provides meals; 4. Chronic CKD stage 3+ or currently receiving dialysis treatment; 5. History of GI surgery involving removal of part of the stomach or intestines; 6. Type 1 or Type 2 diabetes; 7. Autoimmune or Inflammatory disease or immunocompromised; and 8. Cachexia. We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners
Study design
Enrollment target: 30 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-11
Estimated completion: 2028-09-01
Last updated: 2026-11-16
Interventions
Dietary Supplement: Explore the effect of MedDiet vs. Usual Diet on Fatty Acid ProfileDiagnostic Test: Explore the effect of MedDiet vs. Usual Diet on Breast Tumor TissueDiagnostic Test: Explore the effect of MedDiet vs. Usual Diet on LipidsDiagnostic Test: Explore the effect of MedDiet vs. Usual Diet on tumor tissue expression
Primary outcomes
  • • Aim 1a (3 weeks)
  • • Aim 1b (3 weeks)
  • • Aim 1c (3 weeks)
Sponsor
University of Illinois Chicago · other
Contacts & investigators
ContactLisa Marie Tussing-Humphreys, Ph.D. · contact · tussing@uic.edu · 312 355 5521
ContactMeredith Russell · contact · mrussel3@uic.edu · 312 355 5112
InvestigatorLisa Marie Tussing-Humphreys, Ph.D · principal_investigator, University of Illinois Chicago Campus
All locations (1)
University of Illinois at Chicago CampusRecruiting
Chicago, Illinois, United States
BRE-13: Mediterranean Diet · TrialPath